India, Feb. 5 -- India's Contract Research, Development and Manufacturing Organisation (CRDMO) sector is entering a phase of sustained and structural expansion. A 2025 report by Boston Consulting Group (BCG) and the Innovative Pharmaceutical Services Organisation (IPSO) projects that India's CRDMO market could reach $ 22-25 billion by 2035, while McKinsey & Company estimates that India could account for 8-10% of global CDMO outsourcing by 2033 as innovators diversify supply chains and seek resilient, end-to-end partners.

Yet, these numbers tell only part of the story. For much of the past decade, India's role in global pharmaceutical outsourcing was defined narrowly, efficient execution, strong chemistry and cost advantage. That narrativ...